{"entity":{"id":"nct07854509","kind":"trial","name":"A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure","aka":[],"tldr":"A phase 2 trial of CR-001 run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., not yet recruiting.","summary":"A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure is a phase 2 interventional study registered as NCT07854509 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 110 participants planned, started 2026-10-15. Conditions recorded: Non-Squamous Non-Small Cell Lung Cancer. Interventions recorded: SKB264+SKB118.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07854509","url":"https://clinicaltrials.gov/study/NCT07854509"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cr-001"],"companies":["crescent-biopharma","kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07854509","phase":"2","setting":"A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer in Participants Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07854509/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"cr-001","kind":"drug","name":"CR-001","route":"/drugs/cr-001/"}],"company":[{"id":"crescent-biopharma","kind":"company","name":"Crescent Biopharma","route":"/companies/crescent-biopharma/"},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}